Antibiotic-free genetic selection
From basic cloning to large-scale biomanufacturing, ensuring that only cells carrying the desired genetic construct are maintained is essential. Traditional methods rely on antibiotic resistance markers but these are increasingly seen as a risk for both regulatory compliance and public health.
Syngulon has developed a patented antibiotic-free selection system based on bacteriocins. Our technology leverages their unique properties: bacteriocin-immunity pair. Cells carry the bacteriocin production genes on the plasmid to be maintained and secrete the bacteriocin in the medium, creating a selection pressure. To face this pressure, the plasmid also contains the immunity gene protecting the cells that maintain it while plasmid-free or contaminant cells are eliminated.
This approach offers multiple advantages over antibiotics:
- ✅ Regulatory compliance – eliminates resistance markers, fully aligned with FDA/EMA/USDA expectations.
- ✅ Improved productivity – bacteriocins are small peptides, imposing a lighter metabolic burden and enabling higher yields.
- ✅ Genetic stability – peer-police assures a continuous selection pressure through the whole process.
- ✅ Flexibility – 100% plasmid-based, applicable across standard coli strains without chromosomal modifications.
In short, Syngulon’s bacteriocin-immunity selection system provides a scalable, sustainable, and regulator-ready solution for recombinant protein and plasmid DNA production.
You must be logged in to post a comment.